FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer

Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Jiang and colleagues identified a key role for FAK in regulating the composition of the fibro...

Descripción completa

Detalles Bibliográficos
Autores principales: Symeonides, Stefan N., Anderton, Stephen M., Serrels, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319091/
https://www.ncbi.nlm.nih.gov/pubmed/28239470
http://dx.doi.org/10.1186/s40425-017-0217-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319091/
https://www.ncbi.nlm.nih.gov/pubmed/28239470
http://dx.doi.org/10.1186/s40425-017-0217-6

Ejemplares similares